middl
east
respiratori
syndrom
coronaviru
merscov
continu
spread
sinc
emerg
mortal
rate
potenti
pandem
threat
prophylact
therapi
urgent
need
address
public
health
problem
report
efficaci
vaccin
consist
chimer
viruslik
particl
vlp
express
receptor
bind
domain
rbd
merscov
studi
fusion
canin
parvoviru
cpv
structur
protein
gene
rbd
merscov
selfassembl
chimer
spheric
vlp
svlp
svlp
retain
certain
parvoviru
characterist
abil
agglutin
pig
erythrocyt
structur
morpholog
similar
cpv
virion
immun
svlp
induc
rbdspecif
humor
cellular
immun
respons
mice
svlpspecif
antisera
anim
abl
prevent
pseudotyp
merscov
entri
suscept
cell
neutral
antibodi
titer
reach
ifng
secret
cell
induc
rbd
detect
splenocyt
vaccin
mice
elispot
furthermor
mice
inocul
svlp
adjuv
svlp
vaccin
elicit
thelper
thelper
cellmedi
immun
studi
demonstr
svlp
display
rbd
merscov
promis
prophylact
candid
merscov
potenti
outbreak
situat
middl
east
respiratori
syndrom
coronaviru
merscov
infect
caus
sever
possibl
lethal
acut
respiratori
diseas
human
total
death
case
merscov
report
septemb
june
mortal
rate
consider
concern
import
case
mer
report
countri
worldwid
rais
concern
potenti
pandem
vaccin
best
mean
control
prevent
diseas
licens
prophylaxi
current
avail
merscov
surfac
merscov
particl
compos
spike
glycoprotein
play
crucial
step
viral
life
cycl
interact
dipeptidyl
peptidas
molecul
target
cell
initi
viral
dock
entri
studi
shown
receptorbind
domain
rbd
major
antigen
determin
induct
neutral
antibodi
du
et
al
du
et
al
mou
et
al
therefor
candid
express
rbd
merscov
plausibl
design
effect
vaccin
viruslik
particl
vlp
excel
platform
epitop
present
shown
effici
interact
antigenpres
cell
display
heterolog
epitop
high
densiti
barcena
blanco
parvoviruslik
particl
express
major
structur
protein
insect
cell
stabl
highli
immunogen
martinez
et
al
moreov
canin
parvoviru
cpv
caus
diseas
human
therefor
parvoviruslik
particl
safe
express
platform
parvoviru
vlp
success
use
express
foreign
antigen
induct
robust
b
tcell
respons
miyamura
et
al
casal
et
al
loman
et
al
xu
et
al
rueda
et
al
studi
evalu
efficaci
chimer
cpv
vlp
express
rbd
merscov
structur
integr
vlp
confirm
electron
microscopi
immunogen
parvoviruslik
vlp
evalu
mous
model
infect
nucleotid
encod
spike
glycoprotein
residu
merscov
rbd
genbank
access
codonoptim
highest
express
level
possibl
insect
cell
biochem
synthes
sangon
biotech
china
three
repeat
flexibl
linker
gli
ser
clone
cterminu
rbd
rbd
linker
subclon
salinoti
site
gener
transform
e
coli
cell
recombin
bacmid
contain
rbd
insert
confirm
pcr
recombin
baculovirus
gener
recombin
bacmid
transfect
insect
cell
presenc
liposom
transfect
reagent
follow
bactobac
express
system
manual
invitrogen
usa
supernat
contain
recombin
baculoviru
harvest
day
transfect
viral
stock
design
titer
baculoviru
stock
determin
use
rapid
titrat
kit
bacpakbaculoviru
rapid
titer
kit
clontech
usa
express
protein
confirm
indirect
immunofluoresc
previous
describ
feng
et
al
briefli
insect
cell
maintain
c
tnmfh
medium
supplement
fb
infect
multipl
infect
moi
control
cell
infect
baculoviru
h
post
infect
cultur
plate
fix
paraformaldehyd
room
temperatur
min
wash
tween
pbst
incub
mous
antimerss
polyclon
antibodi
mous
monoclon
antibodi
contain
bovin
serum
albumin
c
h
wash
pbst
cell
stain
fitctag
goat
antimous
igg
evan
blue
dilut
pbst
c
h
wash
cell
examin
fluoresc
microscop
insect
cell
maintain
suspens
cultur
serumfre
medium
life
technolog
usa
c
shake
rpm
cell
infect
recombin
baculoviru
moi
cell
harvest
h
infect
wash
pb
lyse
mm
bicarbon
solut
ice
min
centrifug
g
min
cell
pellet
remov
purifi
chimer
vlp
obtain
quarter
volum
satur
ammonium
sulfat
precipit
min
ice
subsequ
centrifug
g
min
viral
pellet
resuspend
pb
dialyz
overnight
sampl
purifi
svlp
purifi
recombin
rbd
protein
cpv
vlp
lysat
infect
cell
transfer
onto
polyvinyliden
fluorid
pvdf
membran
immobilinp
millipor
usa
sdspage
western
blot
mous
antirbd
monoclon
antibodi
svlp
load
onto
grid
kept
room
temperatur
min
stain
sodium
phosphotungst
examin
directli
transmiss
electron
microscop
tem
immunoelectron
microscopi
iem
svlp
load
onto
formvarco
grid
remov
excess
sampl
solut
incub
mous
antirbd
monoclon
antibodi
wash
pb
grid
stain
goldtag
goat
antimous
igg
antibodi
sigmaaldrich
saintloui
mo
usa
anoth
wash
pb
grid
observ
tem
ha
test
carri
previous
describ
feng
et
al
briefli
ml
serial
dilut
svlp
made
pb
addit
ml
pb
ad
well
ml
vv
pig
erythrocyt
ad
well
h
c
ha
titer
determin
highest
dilut
svlp
agglutin
erythrocyt
thirtytwo
balbc
mice
femal
random
four
group
group
vaccin
intramuscularli
im
gastrocnemiu
muscl
mice
group
given
mg
svlp
mice
group
given
mg
svlp
mix
mg
alum
adjuv
thermo
usa
per
anim
mice
group
given
mg
svlp
mix
mg
polyriboinosin
acid
poli
c
adjuv
sigmaaldrich
saint
loui
mo
usa
mice
group
given
pb
control
ident
vaccin
repeat
initi
administr
group
blood
sampl
obtain
orbit
vein
mice
day
postvaccin
rbdspecif
antibodi
measur
sera
mice
rbdspecif
igg
antibodi
sera
immun
control
mice
measur
indirect
elisa
describ
previous
wang
et
al
briefli
microtit
plate
corn
costar
usa
precoat
ml
purifi
rbd
antigen
final
concentr
mgml
incub
overnight
plate
block
skim
milk
h
c
ml
serial
dilut
serum
sampl
ad
incub
c
h
wash
pbst
ml
hrplabel
goat
antibodi
mous
igg
millipor
usa
ad
dilut
incub
c
h
wash
ml
substrat
tetramethylvenzidin
tmb
sigma
usa
ad
well
incub
min
stop
ml
h
optic
densiti
valu
measur
use
elisa
plate
reader
wavelength
nm
biorad
usa
prepar
merspseudotyp
viru
determin
neutral
antibodi
titer
perform
describ
previous
li
et
al
mg
plasmid
mg
plasmid
cotransfect
cell
supernat
harvest
h
centrifug
remov
cell
debri
store
c
neutral
assay
merspseudotyp
viru
mixtur
contain
equal
volum
serial
dilut
mice
sera
tcid
pseudotyp
viru
incub
c
min
incub
huh
cell
sampl
assay
quadrupl
incub
h
medium
replac
dmem
contain
fetal
bovin
serum
h
incub
c
luciferas
activ
sampl
measur
use
infinit
neutral
dose
nd
calcul
use
graphpad
prism
one
week
second
vaccin
inguin
lymph
node
collect
immun
mice
cell
suspens
stain
monoclon
antibodi
bd
bioscienc
franklin
usa
c
min
two
wash
pb
flow
cytometeri
perform
lsrii
flow
cytomet
bd
bioscienc
data
analyz
flowjo
softwar
splenocyt
harvest
two
week
second
immun
inocul
mice
plate
densiti
cell
per
well
elispot
plate
mabtech
ab
sweden
precoat
detect
ifng
express
purifi
rbd
antigen
ad
final
concentr
mgml
stimul
cytokin
product
rest
assay
carri
accord
manufactur
instruct
spot
form
cell
sfc
count
use
autom
elispot
reader
aid
elispot
readerispot
aid
gmbh
ger
environ
hous
facil
mice
accord
nation
standard
laboratori
anim
requir
china
gb
anim
studi
strictli
conduct
recommend
veterinari
institut
academi
militari
medic
scienc
approv
anim
welfar
ethic
committe
permit
number
strategi
design
svlp
shown
fig
mersrbd
fuse
cpv
gener
chimer
vlp
immunofluoresc
assay
confirm
express
recombin
cell
fig
c
e
also
detect
western
blot
purifi
svlp
antirbd
monoclon
antibodi
fig
immunoblot
monoclon
antibodi
show
detect
cpv
vlp
svlp
sampl
fig
suggest
rbd
assembl
svlp
order
obtain
svlp
morpholog
svlp
subject
neg
stain
electron
microscopi
svlp
diamet
nm
observ
fig
slightli
larger
prepar
approxim
nm
diamet
demonstr
rbd
fuse
selfassembl
chimer
vlp
gilbert
et
al
immunoelectron
microscopi
perform
goldtag
antibodi
rbd
result
show
multipl
gold
particl
bound
svlp
fig
demonstr
rbd
display
surfac
viral
particl
subsequ
hemagglutin
purifi
svlp
investig
shown
svlp
could
hemagglutin
pig
erythrocyt
ha
titer
reach
high
fig
evalu
immunogen
chimer
vlp
mice
immun
im
svlp
svlp
combin
mg
alum
adjuv
svlp
combin
mg
poli
c
adjuv
given
pb
fig
mous
sera
collect
two
week
immun
analyz
rbdspecif
antibodi
respons
igg
elisa
rbdspecif
antibodi
respons
detect
svlp
vaccin
mice
two
week
first
inject
igg
elisa
result
show
immun
mice
abl
induc
robust
humor
respons
specif
rbd
first
vaccin
mice
show
enhanc
antibodi
respons
rbd
receiv
second
immun
fig
highest
igg
antibodi
titer
reach
poli
c
adjuv
group
evalu
mous
sera
abil
inhibit
merspseudotyp
viru
entri
cell
perera
et
al
sera
control
group
show
neutral
activ
wherea
sera
svlp
group
alum
poli
c
adjuvantimmun
mice
neutral
first
vaccin
neutral
activ
boost
second
immun
fig
neutral
antibodi
titer
highest
mice
inject
poli
c
adjuv
svlp
titer
determin
whether
svlp
abl
stimul
cytokin
secret
dendrit
cell
dc
percentag
dc
lymph
node
analyz
flow
cytometri
greater
number
dc
detect
three
immun
group
compar
control
fig
addit
fig
percentag
fig
consider
higher
mice
inject
poli
c
adjuv
svlp
suggest
poli
c
abl
activ
dc
lymph
node
gener
robust
immun
respons
cellmedi
immun
respons
evalu
mous
splenocyt
use
ifng
elispot
assay
poli
c
adjuv
svlp
group
substanti
higher
number
ifng
secret
cell
compar
group
immun
svlp
result
increas
secret
cell
howev
spotform
cell
sfc
produc
immun
svlp
combin
alum
adjuv
appear
differ
control
group
fig
previou
approach
merscov
vaccin
candid
includ
recombin
viral
vector
dna
vaccin
well
proteinbas
platform
dna
vaccin
develop
express
synthet
consensu
antispik
protein
shown
immunogen
mice
nonhuman
primat
nhp
camel
muthumani
et
al
anoth
dna
plasmid
vaccin
express
merscov
glycoprotein
enter
phase
clinic
trial
clinic
trialsgov
addit
deliveri
antigen
way
dna
vaccin
nanoparticl
recombin
viral
vector
modifi
vaccinia
ankara
adenoviru
rbdbase
subunit
vaccin
shown
immunogen
efficaci
mice
andor
nhp
merscov
challeng
du
et
al
muthumani
et
al
wang
et
al
coleman
et
al
song
et
al
volz
et
al
kim
et
al
lan
et
al
lan
et
al
incorpor
foreign
epitop
wildtyp
vlp
result
excel
immun
safe
human
use
grgacic
fig
mice
immun
procedur
rbdspecif
antibodi
neutral
antibodi
merscov
infect
balbc
n
vaccin
im
mg
svlp
mg
svlp
mg
alum
mg
svlp
mg
poli
c
adjuv
control
group
treat
pb
blood
sampl
collect
orbit
vein
mice
immun
two
week
immun
b
elisa
result
show
immun
mice
abl
induc
robust
humor
respons
specif
rbd
serum
igg
titer
reach
second
immun
c
immun
mice
serum
titrat
determin
merspseudotyp
viru
huh
cell
titer
determin
highest
serum
dilut
give
reduct
luciferas
activ
express
fig
flow
cytometri
recruit
andor
activ
dc
lymph
node
immun
mice
inguin
lymph
node
isol
mice
group
day
second
immun
stain
mous
monoclon
antibodi
doubleposit
b
cell
plot
data
repres
deviat
sd
doubleposit
cell
percentag
statist
analysi
four
group
analyz
oneway
anova
p
p
anderson
vlp
deriv
hepat
b
viru
ye
et
al
newcastl
diseas
viru
schmidt
et
al
cullen
et
al
parvoviru
gilbert
et
al
gilbert
et
al
shown
suitabl
candid
express
foreign
epitop
present
studi
demonstr
recombin
cpv
link
mer
rbd
result
selfassembl
svlp
display
rbd
surfac
show
vaccin
candid
abl
induc
robust
band
tcell
respons
mice
lack
anim
model
recapitul
symptom
human
infect
merscov
constitut
challeng
evalu
efficaci
vaccin
merscov
modjarrad
van
doremalen
munster
current
anim
model
includ
transgen
mice
nonhuman
primat
model
costli
obtain
therefor
decid
first
test
vaccin
candid
regimen
immunogen
safeti
readili
avail
balbc
mous
model
assess
specif
immun
respons
advanc
bestperform
candid
suitabl
anim
model
merscov
specif
humor
cellmedi
immun
essenti
effect
vaccin
mani
pathogen
slifka
amanna
studi
mice
receiv
svlp
produc
respons
high
level
secret
wherea
mice
immun
svlp
poli
c
produc
substanti
ifng
respons
repres
mix
respons
contrast
mice
receiv
svlp
alum
result
detect
cellular
immun
respons
like
alum
known
poor
cellular
immun
respons
induc
maughan
et
al
contrast
poli
c
doublestrand
rna
polym
act
molecular
mimic
viral
infect
recogn
tolllik
receptor
result
express
ifnab
cytokin
ichinoh
et
al
furthermor
poli
c
use
mani
clinic
trial
good
result
okada
et
al
rahimian
et
al
percentag
doubleposit
cell
notabl
increas
mice
receiv
regim
contain
svlp
suggest
svlp
could
effici
recruit
activ
dc
lymph
node
import
effect
stimul
innat
immun
respons
link
adapt
immun
respons
grgacic
anderson
addit
highest
mice
inject
poli
c
adjuv
svlp
igg
level
highest
poli
c
adjuv
group
summari
poli
c
adjuv
svlp
promis
vaccin
regimen
next
stage
preclin
test
larger
anim
model
dosag
rout
administr
interv
immun
need
evalu
optim
maxim
chanc
success
vaccin
